TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34650132

Group type: EXPERIMENTAL
Intervention: Endometriosis-associated pain symptoms (pelvic pain, pain after/during sexual intercourse, painful menstrual periods)
Number of subjects: 27840

Group type: EXPERIMENTAL
Intervention: Painful periods
Number of subjects: 27840

Group type: EXPERIMENTAL
Intervention: Heavy/irregular bleeding
Number of subjects: 27840

Group type: EXPERIMENTAL
Intervention: Pelvic pain
Number of subjects: 27840

Group type: EXPERIMENTAL
Intervention: Mood impact due to endometriosis
Number of subjects: 27840
Study: 34650392

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control (no lifestyle intervention)
Number of subjects: 1200
Study: 34650509

Group type: EXPERIMENTAL
Intervention: Endovascular recanalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 0
Study: 34650930

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with corticosteroids (5 mg/kg, two to four cycles)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 123
Study: 34651137

Group type: EXPERIMENTAL
Intervention: Enteral dextrose infusion (50% dextrose; 0.5 g/mL) at 10 mL per hour for 24 hours
Number of subjects: 58

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 58
Study: 34651222

Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (5 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (12.5 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (25 mg)
Number of subjects: 2
Study: 34651227

Group type: EXPERIMENTAL
Intervention: Hybrid nomograms combining RS with IPI
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: TMTV-based hybrid nomograms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: MBV-based hybrid nomograms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: TMTV- and MBV-based hybrid nomograms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hybrid nomograms
Number of subjects: 152
Study: 34651291

Group type: EXPERIMENTAL
Intervention: CXCR4-directed PET/CT
Number of subjects: 26
Study: 34652548

Group type: EXPERIMENTAL
Intervention: SAVI SCOUT® reflector (SAVI)
Number of subjects: 25
Study: 34652551

Group type: EXPERIMENTAL
Intervention: Multi-modality image sets: in vivo T2-weighted (T2w)-MRI, 22-min dynamic
Number of subjects: 0
Study: 34652768

Group type: EXPERIMENTAL
Intervention: Dementia residents who died within 6 months (n=240)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Dementia residents
Number of subjects: 2688
Study: 34653030

Group type: EXPERIMENTAL
Intervention: Smartphone-connected hearing aids controlled by a prototype app
Number of subjects: 8
Study: 34653210

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) with Hizentra every 7±2 days for 24 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) with Hizentra
Number of subjects: 15
Study: 34653238

Group type: EXPERIMENTAL
Intervention: NNK genetic cluster (58% of cases)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: DMT genetic cluster (32% of cases)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Immune-suppressive SMZL (50% of cases)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Immune-silent SMZL (50% of cases)
Number of subjects: 303
Study: 34653242

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 mg PO twice daily until progression
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 52
Study: 34653252

Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg twice daily for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg once daily at bedtime for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg once daily in the evening for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crinecerfont 50 mg once daily at bedtime for 14 days
Number of subjects: 18
Study: 34653374

Group type: EXPERIMENTAL
Intervention: Longitudinal latent class analysis identified two distinct subphenotypes.
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Modelling ventilatory ratio and mechanical power parameters.
Number of subjects: 1007
Study: 34653525

Group type: EXPERIMENTAL
Intervention: 1.5 Gy whole-lung LD-RT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard drug treatments without LD-RT
Number of subjects: 40
Study: 34653567

Group type: EXPERIMENTAL
Intervention: Tandem T Slim X2™ with Basal-IQ™ (TTSX2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Medtronic Minimed 640G™ with SmartGuard (MM640G)
Number of subjects: 44
Study: 34654246

Group type: EXPERIMENTAL
Intervention: Nursing homes located in rural areas
Number of subjects: 5926

Group type: EXPERIMENTAL
Intervention: Pharmacy for internal use (PUI)
Number of subjects: 5926

Group type: EXPERIMENTAL
Intervention: Implementation of a personalized care project
Number of subjects: 5926
Study: 34654263

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 3000

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 3000
Study: 34654283

Group type: EXPERIMENTAL
Intervention: Pharmaceutical recommendations by clinical pharmacists
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diuretic therapy recommendations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comprehensive algorithm for pharmacotherapeutic evaluation
Number of subjects: 30
Study: 34654375

Group type: EXPERIMENTAL
Intervention: Relationship characteristics measured with self-report measures and the Partnership Approach Questionnaire.
Number of subjects: 300
Study: 34654464

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) plus treatment as usual (TAU)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced self-help intervention (self-help guide book, 12-h workshop, 1-h individual vocational guidance) plus TAU
Number of subjects: 200
Study: 34654792

Group type: EXPERIMENTAL
Intervention: 1-h automated office blood pressure measurement
Number of subjects: 562

Group type: COMPARATOR
Intervention: Conventional home blood pressure monitoring
Number of subjects: 562
Study: 34655331

Group type: EXPERIMENTAL
Intervention: Dynamic graded upper-body exercise in cold (-15°C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Static graded upper-body exercise in cold (-15°C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heavy dynamic exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dynamic graded upper-body exercise in neutral (+22°C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static graded upper-body exercise in neutral (+22°C)
Number of subjects: 20
Study: 34655377

Group type: EXPERIMENTAL
Intervention: Bhattacharjee pupil expansion ring
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adverse events during surgery
Number of subjects: 25
Study: 34655570

Group type: EXPERIMENTAL
Intervention: EGCG solution
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: EGCG solution with casein addition
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (water) exposure
Number of subjects: 37
Study: 34655683

Group type: EXPERIMENTAL
Intervention: Computed tomography scans every 6 months over 2 years
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Baseline AAA volume, tortuosity, MTD, current tobacco use, angiotensin II receptor blocker use, and history of diabetes mellitus
Number of subjects: 250
Study: 34655838

Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone acetate and prednisone (AAD arm)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Apalutamide (APA arm)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Apalutamide plus abiraterone acetate and prednisone (APA plus AAP arm)
Number of subjects: 128
Study: 34655839

Group type: EXPERIMENTAL
Intervention: Triplet therapy with pembrolizumab (PEM) 200 mg every three weeks, encorafenib (ENC) 450 mg once daily, and binimetinib (BIN) 45 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triplet therapy with PEM, ENC, and BIN
Number of subjects: 15
Study: 34655863

Group type: EXPERIMENTAL
Intervention: Supervised overfeeding for 8 weeks
Number of subjects: 25
Study: 34656090

Group type: EXPERIMENTAL
Intervention: Organizational intervention providing consultation and technical assistance on safety and ergonomics, work intensity, and job enrichment over 13 months.
Number of subjects: 0
Study: 34656103

Group type: EXPERIMENTAL
Intervention: Shape-sensing robotic-assisted bronchoscopy (SSRAB, Ion™ Endoluminal System)
Number of subjects: 60
Study: 34656119

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (Ticagrelor and Clopidogrel)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ticagrelor vs Clopidogrel
Number of subjects: 120
Study: 34656148

Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of IL-17 and IL-23 inhibitors, with dosing intervals prolonged stepwise to achieve 66% and 50% of the original dose.
Number of subjects: 244

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 244
Study: 34656173

Group type: EXPERIMENTAL
Intervention: Internet-based occupational therapy intervention 'Strategies for Empowering activities in Everyday life' (SEE, version 1.0)
Number of subjects: 0
Study: 34656469

Group type: EXPERIMENTAL
Intervention: Fibrin-binding radiotracer using PET/CMR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 0
Study: 34656551

Group type: EXPERIMENTAL
Intervention: Contraceptive method that improved sex life 'a lot' at 1 month
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Contraceptive method that improved sex life 'a little' at 1 month
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Less or no vaginal bleeding
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Worsening of physical side effects
Number of subjects: 1879
Study: 34657151

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy)
Number of subjects: 145
Study: 34657341

Group type: EXPERIMENTAL
Intervention: Post-Acute Stroke Services (COMPASS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 34657357

Group type: EXPERIMENTAL
Intervention: BRCA mutations present
Number of subjects: 298

Group type: COMPARATOR
Intervention: BRCA mutations absent
Number of subjects: 298
Study: 34657389

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d during the Maintenance Period
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d during the Titration Period
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 73
Study: 34657733

Group type: EXPERIMENTAL
Intervention: BICAMS (Brief International Cognitive Assessment in MS)
Number of subjects: 96
Study: 34657825

Group type: EXPERIMENTAL
Intervention: Smartphone app with live health coaching
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 118
Study: 34658014

Group type: EXPERIMENTAL
Intervention: Colchicine plus standard care
Number of subjects: 11525

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 11525
Study: 34658886

Group type: EXPERIMENTAL
Intervention: Preoperative music intervention (20-min music session through earphones before surgery)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (earphones without music)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Preoperative music intervention
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 243
Study: 34659081

Group type: EXPERIMENTAL
Intervention: Prasinezumab, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34659107

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34659208

Group type: EXPERIMENTAL
Intervention: Allocetra™-OTS (early apoptotic cell) infusion
Number of subjects: 10
Study: 34659886

Group type: EXPERIMENTAL
Intervention: Sintilimab monotherapy (2/3 L cohorts)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (1 L cohorts)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sintilimab (2/3 L cohorts)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sintilimab alone or combined with chemotherapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 207
Study: 34660302

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NCT) including adriamycin plus cyclophosphamide followed by intravenous docetaxel for 24 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: Neoadjuvant Endocrine Therapy (NET) involving goserelin acetate and daily tamoxifen for 24 weeks
Number of subjects: 187
Study: 34660457

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lactose granules (placebo)
Number of subjects: 132
Study: 34660617

Group type: EXPERIMENTAL
Intervention: Early post-operative transcutaneous electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34660654

Group type: EXPERIMENTAL
Intervention: KOKO Plus (macronutrient- and micronutrient-fortified complementary food supplement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 34660661

Group type: EXPERIMENTAL
Intervention: Mild malnutrition
Number of subjects: 4863
Study: 34660712

Group type: EXPERIMENTAL
Intervention: Folic Acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard care)
Number of subjects: 0
Study: 34660853

Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 1
Study: 34661177

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo-chemotherapy
Number of subjects: 125
Study: 34661873

Group type: EXPERIMENTAL
Intervention: Moderate to severe grey matter abnormalities
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Moderate to severe ventricular dilatation abnormalities
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Biparietal corrected diameters moderate abnormal
Number of subjects: 114
Study: 34661885

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD and 30 mg QD
Number of subjects: 0
Study: 34661903

Group type: EXPERIMENTAL
Intervention: Folic acid 400 µg/d (FA400)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Folic acid 800 µg/d (FA800)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Folic acid 400 µg/d (FA400) plus creatine (3 g/d)
Number of subjects: 822
Study: 34662125

Group type: EXPERIMENTAL
Intervention: ATX-targeted PET radioligand
Number of subjects: 0
Study: 34662285

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) delivered via telemental health; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control intervention not available.
Number of subjects: 0
Study: 34662378

Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) based on a 9-cellular component model reflecting tumor microenvironment (TME) composition.
Number of subjects: 246
Study: 34662523

Group type: EXPERIMENTAL
Intervention: Transcranial Near-Infrared Light 1068 nm
Number of subjects: 0
Study: 34662778

Group type: EXPERIMENTAL
Intervention: Glutamate + glutamine (Glx) levels in the dorsal anterior cingulate cortex (dACC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Positive resting state functional connectivity (FC) of the salience network (SN)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Negative resting state functional connectivity (FC) of the salience network (SN)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glx-FC associations in the salience network (SN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Glx levels in healthy controls (HC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glx levels in first episode psychosis (FEP)
Number of subjects: 70
Study: 34662857

Group type: EXPERIMENTAL
Intervention: Global Lung Ultrasound Score (LUS)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Subpleural consolidation and pleural line abnormalities
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Examinations within 24 hours of intubation
Number of subjects: 137
Study: 34663154

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Duodenal ulcers
Number of subjects: 543
Study: 34663193

Group type: EXPERIMENTAL
Intervention: Combined high-intensity interval training circuit (HIIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 55
Study: 34663208

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: UST trough concentration > 1.12 μg/mL
Number of subjects: 19
Study: 34663224

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided automated spinal landmark identification program
Number of subjects: 48
Study: 34663254

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET-CT
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional imaging (CT/MRI)
Number of subjects: 156
Study: 34663435

Group type: EXPERIMENTAL
Intervention: Prostate Cancer Imaging Stewardship (PCIS) intervention, which includes audit and feedback, academic detailing, and Clinical Order Check.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implies standard practice without the intervention.
Number of subjects: 0
Study: 34663439

Group type: EXPERIMENTAL
Intervention: NGS-based digital precision diagnostics combined with standard-of-care microbiological analyses
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard-of-care microbiological analyses
Number of subjects: 410
Study: 34663474

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham dry needling (sham DN)
Number of subjects: 21
Study: 34663479

Group type: EXPERIMENTAL
Intervention: High lactate clearance (HLC) group (initial 24 h LC ≥ 64%, n = 333)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Low lactate clearance (LLC) group (n = 295)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: HLC group
Number of subjects: 628

Group type: COMPARATOR
Intervention: LLC group
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Initial serum lactate > 5 mmol/L
Number of subjects: 628

Group type: COMPARATOR
Intervention: Initial serum lactate ≤ 5 mmol/L
Number of subjects: 628
Study: 34663588

Group type: EXPERIMENTAL
Intervention: DRAUP deimplementation programme
Number of subjects: 0
Study: 34663638

Group type: EXPERIMENTAL
Intervention: Tremelimumab (75 mg intravenous) plus Durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by Durvalumab maintenance every 4 weeks (up to nine doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Post-treatment evaluation of the bone microenvironment
Number of subjects: 26
Study: 34663640

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 153
Study: 34663650

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation programme (including physical, occupational, and speech therapy)
Number of subjects: 0
Study: 34663657

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 0
Study: 34663687

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34663746

Group type: EXPERIMENTAL
Intervention: PREFER-HF trial
Number of subjects: 3000
Study: 34664183

Group type: EXPERIMENTAL
Intervention: Microgynon (ethinylestradiol 30 μg and levonorgestrel 150 μg) administered before nintedanib and after nintedanib 150 mg twice daily for ≥ 10 consecutive days.
Number of subjects: 15
Study: 34664224

Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation
Number of subjects: 62
Study: 34664427

Group type: EXPERIMENTAL
Intervention: Mevidalen (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mevidalen (titration from 15 to 75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34664531

Group type: EXPERIMENTAL
Intervention: Lanreotide PRF (prolonged-release formulation) administered every 12 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lanreotide PRF
Number of subjects: 9
Study: 34664789

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1051)
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 641)
Number of subjects: 3275

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1087)
Number of subjects: 3275

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 496)
Number of subjects: 3275
Study: 34665002

Group type: EXPERIMENTAL
Intervention: Immune-based treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene expression profile and genetic mutations comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune-related gene expression and diversity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers for cancer relapse, diagnosis, and prognosis
Number of subjects: 0
Study: 34665133

Group type: EXPERIMENTAL
Intervention: Attempted finger movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Years since SCI
Number of subjects: 0
Study: 34665142

Group type: EXPERIMENTAL
Intervention: Virtual Multimedia Interactive Informed Consent (VIC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional paper consent
Number of subjects: 50
Study: 34665631

Group type: EXPERIMENTAL
Intervention: CHK1 Inhibitor Candidate (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 34665659

Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound Guidance in Stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34665780

Group type: EXPERIMENTAL
Intervention: Intracortical microelectrode array stimulation (96 electrodes)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation via multiple electrodes
Number of subjects: 1